{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:30:43Z","timestamp":1753878643217,"version":"3.41.2"},"reference-count":66,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet Med"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dapagliflozin (SGLT\u20102 inhibitor) and sotagliflozin (SGLT1\/2 inhibitor) are two of the drugs of SGLT inhibitor class which have been recommended by the National Institute for Health and Care Excellence (NICE) in people with type 1 diabetes with BMI \u226527\u00a0kg\/m<jats:sup>2<\/jats:sup>. Dapagliflozin is licensed in the UK for use in the NHS while sotagliflozin may be available in future. These and possibly other SGLT inhibitors may be increasingly used in people with type 1 diabetes as new licences are obtained. These drugs have the potential to improve glycaemic control in people with type 1 diabetes with the added benefit of weight loss, better control of blood pressure and more time in optimal glucose range. However, SGLT inhibitors are associated with a higher incidence of diabetic ketoacidosis without significant hyperglycaemia. The present ABCD\/Diabetes UK joint updated position statement is to guide people with type 1 diabetes and clinicians using these drugs help mitigate this risk and other potential complications. Particularly, caution needs to be exercised in people who are at risk of diabetic ketoacidosis due to low calorie diets, illnesses, injuries, starvation, excessive exercise, excessive alcohol consumption and reduced insulin administration among other precipitating factors for diabetic ketoacidosis.<\/jats:p>","DOI":"10.1111\/dme.14458","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T07:14:14Z","timestamp":1605165254000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium\u2013glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020)"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-1852","authenticated-orcid":false,"given":"Umesh","family":"Dashora","sequence":"first","affiliation":[{"name":"Conquest Hospital Hastings UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipesh C.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Medicine University College London Royal Free Campus London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-8895","authenticated-orcid":false,"given":"Robert","family":"Gregory","sequence":"additional","affiliation":[{"name":"University Hospitals of Leicester NHS Trust Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1787-7496","authenticated-orcid":false,"given":"Peter","family":"Winocour","sequence":"additional","affiliation":[{"name":"ENHIDE, East and North Hertfordshire NHS Trust Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-9579","authenticated-orcid":false,"given":"Ketan","family":"Dhatariya","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospitals NHS Foundation Trust UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Rowles","sequence":"additional","affiliation":[{"name":"Pennine Acute Hospitals NHS Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Macklin","sequence":"additional","affiliation":[{"name":"Dorset County Hospital Foundation Trust Dorchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-7015","authenticated-orcid":false,"given":"Gerry","family":"Rayman","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospitals NHS Foundation Trust UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Nagi","sequence":"additional","affiliation":[{"name":"Edna Coates Diabetes and Endocrine Unit Pinderfields Hospital Wakefield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ABCD executive committee, supported by Diabetes UK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Institute for Health and Clinical Excellence (NICE).Dapagliflozin with insulin for treating type 1 diabetes. NICE guidance. London 2020.https:\/\/www.nice.org.uk\/guidance\/ta597(Accessed 29 August 2020)"},{"key":"e_1_2_9_3_1","unstructured":"National Institute for Health and Clinical Excellence (NICE).Sotagliflozin with insulin for treating type 1 diabetes. NICE guidance. London 2020.https:\/\/www.nice.org.uk\/guidance\/ta622(Accessed 29 August 2020)"},{"key":"e_1_2_9_4_1","unstructured":"National Institute for Health and Clinical Excellence (NICE).Type 1 diabetes in adults: diagnosis and management. NICE guidance. London 2016.https:\/\/www.nice.org.uk\/guidance\/ng17(accessed 29 August 2020)"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2316"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051013-110046"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.113"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.15277\/\/bjd.2019.208"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.15277\/bjd.2018.184"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-1565"},{"key":"e_1_2_9_14_1","unstructured":"National Institute for Health and Clinical Excellence (NICE).Cardiovascular disease: risk assessment and reduction including lipid modification. NICE guidance.2016.https:\/\/www.nice.org.uk\/guidance\/cg181(accessed 28 August 2020)"},{"key":"e_1_2_9_15_1","unstructured":"The healthcare quality improvement partnership.National Diabetes Audit Report 2019.https:\/\/digital.nhs.uk\/data\u2010and\u2010information\/publications\/statistical\/national\u2010diabetes\u2010audit\/national\u2010diabetes\u2010audit\u2010quarterly\u2010report\u2010january\u2010to\u2010december\u20102019#summary(accessed 28 August 2020)"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1889"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-311050"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1213"},{"key":"e_1_2_9_19_1","unstructured":"SharpP KilvertA DashoraU et al.Standards of care for management of adults with type 1 diabeteshttps:\/\/abcd.care\/sites\/abcd.care\/files\/site_uploads\/Type_1_standards_of_care.pdf. (accessed 28 August 2020)"},{"key":"e_1_2_9_20_1","unstructured":"SharpP KilvertA DashoraU GregoryR WilmotE AtkinM et al.Standards of care for management of adults with type 1 diabetes updatedhttps:\/\/abcd.care\/sites\/abcd.care\/files\/resources\/Standards_of_Care_T1DM_ABCD_FINAL.pdf(accessed 28 August 2020)"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2112"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.2.140"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1636-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12948"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13863"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.15277\/bjdvd.2014.022"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399815666190614141918"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.08.022"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.04.018"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00728-6"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2955"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12494"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0261"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1353"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1730"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12975"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1087"},{"key":"e_1_2_9_39_1","first-page":"325","article-title":"Short and medium\u2010term efficacy of sodium glucose cotransporter\u20102 (SGLT\u20102) Inhibitors for the treatment of type 1 diabetes: Systematic review and meta\u2010analysis","volume":"71","author":"Huang Y","year":"2020","journal-title":"Endokrynologia Polska"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020875"},{"key":"e_1_2_9_41_1","unstructured":"EMA.EMA accepts marketing authorisation variation for Forxiga in adults with type 1 diabetes. Available athttps:\/\/www.europeanpharmaceuticalreview.com\/news\/73381\/ema\u2010forxiga\u2010type\u20101\u2010diabetes\/(accessed 29 August 2018)"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1451"},{"key":"e_1_2_9_43_1","first-page":"1","article-title":"A systematic review and meta\u2010analysis of randomised controlled trials, contrasting the safety profile between sodium\u2010glucose cotransporter\u20102 inhibitors and placebo in type 1 diabetes mellitus patients","author":"Saha S","year":"2020","journal-title":"International Journal of Diabetes and Metabolism"},{"journal-title":"Diabetes Obes Metab.","article-title":"Evaluation of the safety of SGLT\u20102 inhibitors for treating patients with type 1 diabetes","author":"Wang W","key":"e_1_2_9_44_1"},{"journal-title":"Journal of Diabetes Investigation","article-title":"Sodium\u2010glucose cotransporter inhibitors as add\u2010on therapy in addition to insulin for type 1 diabetes mellitus: A meta\u2010analysis of randomized controlled trials","author":"Zou H","key":"e_1_2_9_45_1"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4301-8"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2338"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1356"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2579"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111658"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12882"},{"journal-title":"Diabetes & metabolism","article-title":"Risks of diabetic foot syndrome and amputation associated with sodium glucose co\u2010transporter 2 inhibitors: A meta\u2010analysis of randomized controlled trials","author":"Li D","key":"e_1_2_9_55_1"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234065"},{"key":"e_1_2_9_57_1","first-page":"108136","article-title":"Risk of amputation associated with sodium\u2010glucose co\u2010transporter 2 inhibitors: A meta\u2010analysis of five randomized controlled trials","author":"Miyashita S","journal-title":"Diabetes Res Clin Pract"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13424"},{"key":"e_1_2_9_59_1","unstructured":"Gov. UK.SGLT2 inhibitors: Updated advice on increased risk of lower\u2010limb amputation (mainly toes)https:\/\/www.gov.uk\/drug\u2010safety\u2010update\/sglt2\u2010inhibitors\u2010updated\u2010advice\u2010on\u2010increased\u2010risk\u2010of\u2010lower\u2010limb\u2010amputation\u2010mainly\u2010toes(accessed 28 August 2020)"},{"key":"e_1_2_9_60_1","unstructured":"British cardiovascular society.Guide for non\u2010diabetes specialist physicians and primary care teams for cardiovascular risk optimisation in patients with type 2 diabetes and atherosclerotic cardiovascular disease (coronary artery disease peripheral arterial disease cerebrovascular disease)https:\/\/www.britishcardiovascularsociety.org\/__data\/assets\/pdf_file\/0021\/21963\/CaReMe_T2DM_CVD_2020.pdf(accessed 20 September 2020)"},{"key":"e_1_2_9_61_1","unstructured":"European Medicines Agency.SGLT2 inhibitors (previously canagliflozin)https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/sglt2\u2010inhibitors\u2010previously\u2010canagliflozin(accessed 2 September 2020)"},{"issue":"43","key":"e_1_2_9_62_1","first-page":"487","article-title":"A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"2020","author":"Buse JB","year":"2018","journal-title":"Diabetes Care"},{"key":"e_1_2_9_63_1","unstructured":"US Food and Drugs Administration.FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana Invokamet Invokamet XR)https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010removes\u2010boxed\u2010warning\u2010about\u2010risk\u2010leg\u2010and\u2010foot\u2010amputations\u2010diabetes\u2010medicine\u2010canagliflozin(accessed 2nd September 2020)"},{"journal-title":"Diabetes Obes Metab","article-title":"SGLT2 inhibitors and stroke risk in patients with type 2 diabetes: A systematic review and meta\u2010analysis","author":"Guo M","key":"e_1_2_9_64_1"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018245"},{"key":"e_1_2_9_66_1","first-page":"e13339","article-title":"SGLT2 inhibition and COVID\u201019: The road not taken","author":"Das L","journal-title":"Eur J Clin Invest"},{"key":"e_1_2_9_67_1","unstructured":"ClinicalTrials.gov.Dapagliflozin in Respiratory Failure in Patients with COVID\u201019 (DARE\u201019).2020(Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04350593(accessed 29 August 2020)"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.14458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dme.14458","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.14458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T15:29:40Z","timestamp":1693582180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.14458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/dme.14458"],"URL":"https:\/\/doi.org\/10.1111\/dme.14458","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"type":"print","value":"0742-3071"},{"type":"electronic","value":"1464-5491"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"2020-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14458"}}